PUBLISHER: Coherent Market Insights | PRODUCT CODE: 2184318
PUBLISHER: Coherent Market Insights | PRODUCT CODE: 2184318
Theranostics Market is estimated to be valued at USD 11.4 Bn in 2026 and is expected to reach USD 28.8 Bn by 2033, growing at a compound annual growth rate (CAGR) of 10.9% from 2026 to 2033.
| Report Coverage | Report Details | ||
|---|---|---|---|
| Base Year: | 2025 | Market Size in 2026: | USD 11.4 Bn |
| Historical Data for: | 2020 to 2024 | Forecast Period: | 2026 to 2033 |
| Forecast Period 2026 to 2033 CAGR: | 10.90% | 2033 Value Projection: | USD 28.8 Bn |
The market is undergoing significant transformation, mainly driven by the rising adoption of personalized medicine, targeted therapies, companion diagnostics, molecular imaging, and precision oncology. Theranostics combines diagnostic technologies with targeted therapeutic approaches to identify disease-specific biomarkers, select appropriate patients, guide treatment decisions, and monitor therapeutic response.
The market includes a broad range of technologies such as polymerase chain reaction (PCR), immunohistochemistry, in situ hybridization, and sequencing, which support biomarker detection and patient stratification across oncology and other therapeutic areas. Growing use of radiotheranostics is further strengthening the integration of molecular imaging with targeted radiopharmaceutical therapies, particularly in prostate cancer and neuroendocrine tumors. Advances in genomic profiling, companion diagnostics, molecular imaging, and targeted drug delivery are improving the ability of healthcare providers to deliver more individualized treatment strategies.
Healthcare providers are increasingly investing in nuclear medicine infrastructure, advanced imaging systems, molecular diagnostic platforms, and specialized oncology capabilities. The expansion of PET and SPECT imaging, radiopharmaceutical production, biomarker testing, and genomic profiling is improving theranostic workflows and supporting wider clinical adoption. Hospitals and diagnostic laboratories are also strengthening their capabilities to integrate diagnostic testing with targeted therapeutic decision-making.
The market is witnessing strong momentum owing to the increasing prevalence of cancer, rising demand for personalized medicine, and growing adoption of biomarker-based diagnosis and targeted therapies. Healthcare providers are increasingly using molecular diagnostics, genomic profiling, companion diagnostics, and advanced imaging technologies to identify actionable biomarkers and select patients who are more likely to benefit from specific treatments.
The growing adoption of radiotheranostics is a major factor supporting market expansion. Radiotheranostic approaches combine molecular imaging with therapeutic radiopharmaceuticals using the same or closely related molecular targets. This approach is increasingly being adopted in areas such as prostate cancer and neuroendocrine tumors, where molecular imaging can identify eligible patients before targeted radioligand therapy is administered.
Expansion of nuclear medicine infrastructure and molecular diagnostic capabilities is also fueling market growth. Hospitals and specialized cancer centers are investing in PET and SPECT imaging, radiopharmaceutical production and handling capabilities, molecular laboratories, and multidisciplinary oncology teams. Supportive reimbursement policies for advanced diagnostic radiopharmaceuticals are further helping improve access to theranostic procedures.
The rising global cancer burden is further strengthening demand for advanced diagnostic and treatment solutions. Growing use of biomarker testing enables clinicians to identify molecular abnormalities, improve patient stratification, and select targeted therapies based on individual disease characteristics. At the same time, advances in PCR, sequencing, liquid biopsy, and genomic profiling are broadening the role of molecular diagnostics across theranostic workflows.
However, wider adoption of theranostics depends on the availability of specialized nuclear medicine infrastructure, trained healthcare professionals, reliable radioisotope production, and efficient distribution networks. Expansion of radioligand therapy is therefore expected to create opportunities for investments across radiopharmaceutical manufacturing, molecular imaging, diagnostic testing, isotope supply, and specialized treatment centers.
Theranostics Market Segmentation